Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Medicines licensing

FDA approves new HIV combination therapy designed to reduce side effects

A new HIV combination therapy, Genvoya, Pictured, for the treatment of adults and children aged over 12 years has been approved in the United States by the US FDA

Source: Gilead Sciences

The FDA-approved HIV therapy contains tenofovir alafenamide, included to reduce the adverse effects associated with previously approved tenofovir-containing regimens

A new HIV combination therapy for the treatment of adults and children aged over 12 years has been approved in the United States by the US Food and Drug Administration (FDA).

The fixed-dose tablet contains a combination of elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide and is marketed in the United States as Genvoya.

The tablet includes a new form of tenofovir designed to reduce the drug’s side effects: it offers lower levels of the drug in the patient’s bloodstream compared with tenofovir disoproxil but higher levels in the cells where HIV-1 replicates. The combination therapy, which provides patients with a single daily treatment, is associated with less kidney toxicity and decreases in bone density than previously approved tenofovir-containing regimens, the FDA says.

The drug is restricted to children who weigh at least 35kg who have never taken an HIV therapy or adults whose HIV infection is suppressed. It is not recommended for patients with severe renal impairment.

The FDA’s decision was based on the results of four clinical trials involving 3,171 patients who were randomly given Genvoya or another FDA-approved HIV therapy. Genvoya was found to be as effective as other treatments, the FDA says.

The drug — marketed by Gilead Sciences — comes with a boxed warning as it can trigger a build-up of lactic acid in the blood and can cause severe liver problems, both of which can be fatal.

The drug received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use in September 2015. The recommendation is awaiting ratification by the European Commission.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20200033

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • A new HIV combination therapy, Genvoya, pictured, for the treatment of adults and children aged over 12 years has been approved in the United States by the FDA

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.